nalmefene has been researched along with Alcohol Drinking in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.82) | 18.7374 |
| 1990's | 2 (3.64) | 18.2507 |
| 2000's | 6 (10.91) | 29.6817 |
| 2010's | 38 (69.09) | 24.3611 |
| 2020's | 8 (14.55) | 2.80 |
| Authors | Studies |
|---|---|
| Azar, MR; Berzetei-Gurske, I; Cashman, JR; Ghirmai, S; Polgar, WE | 1 |
| Habu, H; Hashimoto, N; Kishi, Y; Matsuo, K; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Yamada, N | 1 |
| Duprez, R; Hammas, K; Ioannidis, JPA; Laviolle, B; Naudet, F; Palpacuer, C | 1 |
| Braillon, A; Naudet, F; Palpacuer, C | 1 |
| Brach, BS; Luderer, M; Meulien, D; Mueller, S; Schou, MB; Zhang, D | 1 |
| Caballeria, E; Gual, A; López-Pelayo, H; Mann, K; Van den Brink, W; Zuluaga, P | 1 |
| Hayashi, T; Higuchi, S; Miyata, H | 1 |
| Tadori, Y | 1 |
| Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Nakamura, I; Takahashi, M; Tsuneyoshi, K | 1 |
| Tamaki, K | 1 |
| Gil, A; Guerri, C; Montesinos, J | 1 |
| Barrio, P; Gual, A; Guardia, J; Ortega, L; Roncero, C; Yuguero, L | 1 |
| Aballéa, S; Daeppen, JB; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Donoghue, K | 1 |
| Hayashi, T; Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Sørensen, P; Takahashi, M; Tsuneyoshi, K | 1 |
| Gual, A; He, Y; Mann, K; Torup, L; van den Brink, W | 1 |
| Aubin, HJ; Daeppen, JB | 1 |
| Keating, GM | 1 |
| Spence, D | 1 |
| Batel, P; Chick, J; Gual, A; Kiefer, F; Sinclair, J; Sørensen, P | 1 |
| Braillon, A | 1 |
| McNulty, SJ; Williams, P | 1 |
| Gual, A; Mann, K; Sørensen, P; Torup, L; van den Brink, W | 1 |
| Barbosa, C; Brodtkorb, TH; Daeppen, JB; François, C; Knight, C; Laramée, P; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Aballéa, S; Bineau, S; Chalem, Y; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Bilbao, A; Heilig, M; Malanga, CJ; Robinson, JE; Sommer, WH; Spanagel, R; Thorsell, A | 1 |
| Bendimerad, P; Blecha, L | 1 |
| Gual, A; Jensen, TJ; Mann, K; Strang, J; Sørensen, P; van den Brink, W | 1 |
| Lieb, M; Soyka, M | 1 |
| Aubin, HJ; Bladström, A; Chick, J; François, C; Nutt, DJ; Reimer, J; Torup, L | 1 |
| Morgan, MY; Pandor, A; Rawdin, A; Rice, P; Stevens, JW; Stevenson, M; Thompson, J | 1 |
| Aubin, HJ; Chalem, Y; François, C; Luquiens, A; Rahhali, N; Sørensen, P | 1 |
| Baroni, S; Dell'Osso, L; Marazziti, D; Mucci, F; Mungai, F; Piccinni, A; Presta, S | 1 |
| Bruhn, C | 1 |
| Sivolap, YP | 1 |
| Franchitto, N; Nubukpo, P; Pélissier, F; Rougé Bugat, ME | 1 |
| Friede, M; Schnitker, J; Soyka, M | 1 |
| Addolorato, G; Bernardi, M; Caputo, F; D'Amore, A; Domenicali, M; Maremmani, AG; Maremmani, I; Zoli, G | 1 |
| Bell, M; Brodtkorb, TH; Irving, AH; Laramée, P | 1 |
| Bühler, KM; Calleja-Conde, J; Echeverry-Alzate, V; Giné, E; Gual, A; López-Moreno, JA; Maldonado, R; Nadal, R; Rodríguez de Fonseca, F | 1 |
| Aballéa, S; Chalem, Y; Cristeau, O; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Aballéa, S; Brodtkorb, TH; Cristeau, O; Laramée, P; Millier, A; Montgomery, S; Rahhali, N; Rehm, J; Steeves, S; Toumi, M | 1 |
| Boussageon, R; Laviolle, B; Naudet, F; Palpacuer, C | 1 |
| Rösner, S; Soyka, M | 1 |
| Bladström, A; Gual, A; Mann, K; Torup, L; van den Brink, W | 1 |
| Anton, RF; Drobes, DJ; Thomas, SE; Voronin, K | 2 |
| Kallio, A; Karhuvaara, S; Löyttyniemi, E; Mäkelä, R; Nurminen, T; Rosberg, M; Simojoki, K; Virta, A | 1 |
| June, HL | 1 |
| Cummings, R; Durr, LF; Grey, C; Johnson, A; June, HL; Lawrence, A; Mason, D; McCane, S; Ricks-Cord, A; Warren-Reese, C; Williams, LS | 1 |
| Cutler, RB; Mason, BJ; Ritvo, EC; Salvato, FR; Williams, LD | 1 |
| Anton, RF; Drobes, DJ | 1 |
| Allen, JI; DeMaster, EG; Go, VL; Ho, SB; Levine, AS; Morley, JE; Shafer, RB | 1 |
12 review(s) available for nalmefene and Alcohol Drinking
| Article | Year |
|---|---|
Safety of nalmefene for the treatment of alcohol use disorder: an update.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Drug Approval; Humans; Naltrexone; Narcotic Antagonists | 2020 |
[Pharmacological profile and clinical findings of nalmefene (Selincro
Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials, Phase III as Topic; Humans; Japan; Multicenter Studies as Topic; Naltrexone; Randomized Controlled Trials as Topic; Rats; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2020 |
Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption.
Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Aripiprazole; Flupenthixol; Fluvoxamine; Fructose; Humans; Naltrexone; Piperazines; Psychotropic Drugs; Quinolones; Topiramate | 2013 |
Nalmefene: a review of its use in the treatment of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Humans; Internationality; Naltrexone; Randomized Controlled Trials as Topic | 2013 |
Bad medicine: nalmefene in alcohol misuse.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents | 2014 |
[Benefits in reducing alcohol consumption: how nalmefene can help].
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Cause of Death; Europe; Female; Humans; Male; Middle Aged; Naltrexone; Risk Factors; Treatment Outcome; Young Adult | 2014 |
Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
Topics: Adult; Alcohol Drinking; Alcoholism; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline | 2015 |
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost-Benefit Analysis; Humans; Naltrexone; Narcotic Antagonists; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Social Support | 2015 |
Nalmefene: A Novel Drug for an Old Disorder.
Topics: Alcohol Drinking; Alcoholism; Animals; Humans; Naltrexone | 2015 |
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
Topics: Adult; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Nalmefene for treatment of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials as Topic; Humans; Naltrexone | 2010 |
16 trial(s) available for nalmefene and Alcohol Drinking
| Article | Year |
|---|---|
Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis.
Topics: Alcohol Drinking; Alcoholism; Ethanol; Humans; Naltrexone; Narcotic Antagonists | 2022 |
Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.
Topics: Alcohol Drinking; Alcoholism; Elasticity; Elasticity Imaging Techniques; Fatty Liver; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2020 |
Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Time Factors | 2020 |
Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatients; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Middle Aged; Naltrexone; Risk; Treatment Outcome | 2019 |
A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2013 |
Can alcohol dependent patients adhere to an 'as-needed' medication regimen?
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Self Care; Treatment Outcome | 2014 |
Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Young Adult | 2014 |
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model.
Topics: Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Naltrexone; Public Health; Risk Assessment; Social Support | 2014 |
Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2015 |
Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
Topics: Alanine Transaminase; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Administration Schedule; Female; gamma-Glutamyltransferase; Humans; Liver; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention | 2013 |
A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Environment; Female; Humans; Male; Middle Aged; Naltrexone | 2003 |
Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Behavior, Addictive; Female; Humans; Male; Middle Aged; Naltrexone | 2004 |
Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Finland; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Patient Compliance; Placebos; Sleep Initiation and Maintenance Disorders; Substance Abuse Treatment Centers; Temperance; Treatment Outcome | 2007 |
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
Topics: Administration, Oral; Alcohol Drinking; Alcoholism; Breath Tests; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Temperance; Treatment Outcome | 1999 |
Drinking in alcoholics following an alcohol challenge research protocol.
Topics: Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Research; Temperance | 2000 |
27 other study(ies) available for nalmefene and Alcohol Drinking
| Article | Year |
|---|---|
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
Topics: Alcohol Drinking; Alcoholism; Amides; Animals; Binding, Competitive; Drug Evaluation, Preclinical; Ethanol; Humans; Hydrogen Bonding; Liver; Mice; Microsomes, Liver; Molecular Structure; Morphinans; Naltrexone; Rats; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship | 2008 |
Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis.
Topics: Alcohol Drinking; Alcoholism; Humans; Meta-Analysis as Topic; Naltrexone; Narcotic Antagonists; Research Design | 2019 |
Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2020 |
Response to 'Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption'.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2020 |
[Four cases of alcoholic liver cirrhosis in alcohol-dependent patients treated with nalmefene].
Topics: Alcohol Drinking; Alcoholism; Europe; Humans; Japan; Liver Cirrhosis, Alcoholic; Naltrexone | 2021 |
Nalmefene Prevents Alcohol-Induced Neuroinflammation and Alcohol Drinking Preference in Adolescent Female Mice: Role of TLR4.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Animals; Astrocytes; Cell Death; Chemokines; Drug Evaluation, Preclinical; Ethanol; Female; Membrane Microdomains; Mice, Inbred C57BL; Mice, Knockout; Myelin Sheath; Naloxone; Naltrexone; Narcotic Antagonists; Primary Cell Culture; Toll-Like Receptor 4 | 2017 |
Cost-Effectiveness of Nalmefene Added to Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol-Dependent Patients With High/Very High Drinking Risk Levels: A Microsimulation Model.
Topics: Alcohol Drinking; Alcoholism; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Naltrexone; Quality-Adjusted Life Years; Risk | 2017 |
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate | 2018 |
Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2014 |
Bad medicine: using surrogate markers.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2014 |
▼Nalmefene for alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Drug Approval; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Prevalence; Sex Factors; United Kingdom | 2014 |
Nalmefene. Alcohol dependence: no advance.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Patient Safety; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome | 2014 |
A predictive microsimulation model to estimate the clinical relevance of reducing alcohol consumption in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Computer Simulation; England; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Models, Theoretical; Naltrexone; Narcotic Antagonists; Wounds and Injuries | 2014 |
A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice.
Topics: Alcohol Drinking; Animals; Conditioning, Operant; Electric Stimulation; Ethanol; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Naltrexone; Receptors, Opioid, mu; Reward; Self Administration | 2015 |
The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Demography; Female; Humans; Male; Middle Aged; Naltrexone; Patient Outcome Assessment; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2015 |
[Reduction of consumption as the first goal of therapy].
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2015 |
[Alcohol use disorders: current approaches to diagnosis and treatment].
Topics: Alcohol Drinking; Alcoholism; Diagnostic and Statistical Manual of Mental Disorders; Ethanol; Female; Humans; International Classification of Diseases; Male; Naltrexone; Narcotic Antagonists; Remission Induction | 2015 |
Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
Topics: Adult; Alcohol Drinking; Analgesics, Opioid; Buprenorphine; Drug Interactions; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2016 |
Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Alcohols; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sodium Oxybate; Treatment Outcome | 2016 |
The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost of Illness; Cost-Benefit Analysis; Crime; Efficiency; Female; Health Care Costs; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Naltrexone; Patient Acceptance of Health Care; Psychotherapy; Risk; United Kingdom; Young Adult | 2016 |
Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.
Topics: Alcohol Drinking; Animals; Cocaine; Dose-Response Relationship, Drug; Drug Interactions; Ethanol; Gene Expression Regulation, Enzymologic; Histone Deacetylases; Male; Naltrexone; Rats; Rats, Wistar; Structure-Activity Relationship | 2016 |
A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Computer Simulation; Europe; Harm Reduction; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Outcome and Process Assessment, Health Care; Public Health; Social Support | 2016 |
A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Female; Humans; Naltrexone | 2016 |
Evaluation in alcohol use disorders - insights from the nalmefene experience.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Female; Harm Reduction; Humans; Male; Naltrexone; Narcotic Antagonists | 2016 |
Preclinical models to evaluate potential pharmacotherapeutic agents in treating alcoholism and studying the neuropharmacological bases of ethanol-seeking behaviors in rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Addictive; Disease Models, Animal; Drug Evaluation, Preclinical; Ethanol; Female; Male; Naltrexone; Rats; Reinforcement Schedule | 2002 |
The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Genotype; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains | 1998 |
Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study.
Topics: Acetaldehyde; Adult; Alcohol Drinking; Asian; Blood Pressure; Body Temperature Regulation; Endorphins; Ethanol; Flushing; Heart Rate; Humans; Hydrocortisone; Male; Naltrexone; Narcotic Antagonists | 1988 |